Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

Share Price is delayed by 15 minutes
Get Live Data
12.95    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.65 (5.285%)
Market Cap: £44.04m
BVC Live PriceLast checked at - London Stock Exchange

Intraday Batm Advanced Share Chart

Directorate Change

23 Jun 2025 07:00

RNS Number : 9028N
BATM Advanced Communications Ld
23 June 2025
 

LEI: 213800FLQUB9J289RU66

23 June 2025

 

BATM Advanced Communications Limited

("BATM" or "the Group") 

 

Directorate Change

 

BATM (LSE: BVC; TASE: BVC), a global provider of advanced network infrastructure, cybersecurity and diagnostic technologies, announces that Ran Noy has resigned as Chief Financial Officer ("CFO") and a Director of the Group and that Leor ("Lior") Miles, CPA, has been appointed as CFO, both with immediate effect. To ensure a smooth transition, Ran will remain with the Group for a period of handover.

 

Lior brings over 15 years' experience in financial management for public and private companies operating globally primarily in the technology industry, including serving as VP Finance of BATM from 2015-2021. He has joined BATM from Kenes Group where, as Group CFO, he oversaw financial operations, including investments, cash management, risk management, insurance, M&A, taxation and financial strategy, for the global operations across 18 locations on four continents. Other experience includes being Director of Finance for Abra Information Technologies Ltd., a TASE-listed provider of IT services and solutions, and its subsidiaries in the US and Israel. He commenced his career as an accountant at PwC, where he performed company audits in accordance with US GAAP and IFRS standards.

 

It is expected that Lior will also be appointed to the Board of BATM subject to, in accordance with the Group's articles of association and the Israeli Companies Law, shareholder approval at a general meeting that is to be convened. The required disclosures pursuant to UK Listing Rules 6.4.8 in relation to Lior will be made in due course.

 

In accordance with Israeli regulation, the Group confirms that the resignation of Ran does not involve any material information that is required to be disclosed to shareholders. The business continues to progress well and no material impact is expected from the current escalation of geopolitical events in the Middle East.

 

Dr. Gideon Chitayat, Chairman of BATM, said: "On behalf of the Board, I would like to thank Ran for his contribution to BATM over a period where we have transformed our business and significantly improved our operations and infrastructure. We are grateful to Ran for his role in this and we wish him all the best for the future. I would also like to welcome Lior back to BATM. He already has familiarity with our business and he returns having gained valuable experience, which we look forward to benefiting from as we move to the next stage of our development and execute on our strategy."

 

Enquiries

 

BATM

 

Moti Nagar, Chief Executive Officer

+972 9866 2525

 

Shore Capital

 

Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

+44 20 7408 4050 

 

 

Gracechurch Group

 

Harry Chathli, Claire Norbury

+44 20 4582 3500

 

Forward-looking statements  

This document contains forward-looking statements. Those statements reflect the current opinions, evaluations and estimations of the Group's management, and are based on the current data regarding the Group's business as is detailed in this document and in the Group's periodical, interim and immediate reports. The Group does not undertake any obligation or make any representation that actual results and events will be in line with those statements, and stresses that they may differ materially from those statements, due to changes in the Group's business, market, competition, demand for the Group's products or services, general economic factors or other factors that can influence the Group's business and results, due to the risk factors that are detailed in the Group's Annual Report, and due to information and factors that are currently unknown to the Group's management and that, if known, would affect the management's opinions, evaluations or estimations. The Group will report the actual results and events according to its legal, accounting and regulatory obligations, and does not undertake any other obligation to report them or their deviations from the forward-looking statements, or to update any of the forward-looking statements in this document or to report that it is not valid anymore.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOABIGDLIXDDGUD
Date   Source Headline
2nd May 20247:00 amRNSBATM selected for TB diagnostics programme
18th Apr 20247:00 amRNSBATM to deliver Edgility to new Tier 1 customer
8th Apr 20247:00 amRNSBATM awarded new Edgility contract from Cemex
3rd Apr 20247:00 amRNSAnnual Financial Report
26th Mar 20247:00 amRNSBATM receives $2.3m cyber security orders
12th Mar 20247:00 amRNSFull Year Results
29th Feb 20247:00 amRNSNotice of Results
2nd Jan 20247:00 amRNSTotal Voting Rights
30th Nov 20237:03 amRNSBlock Listing Application
27th Nov 20237:00 amRNSBlock Listing Interim Review
30th Oct 20237:00 amRNSBATM receives $3m cyber security order
23rd Oct 20237:00 amRNSADOR Diagnostics secures $7.5m investment
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20237:00 amRNSNew Edgility order for US Emergency Services
9th Oct 20237:00 amRNSResponse to recent developments in Israel
6th Sep 20237:00 amRNSBATM receives $3.4m cyber security contract
29th Aug 20237:00 amRNSInterim Results
13th Jul 202311:30 amRNSResult of AGM and Director Appointment
8th Jun 20237:00 amRNSNotice of Annual General Meeting
6th Jun 20237:00 amRNSCapital Markets Day
5th Jun 20237:00 amRNSNew contract win for Edgility
10th May 20232:30 pmRNSCapital Markets Day and Investor Presentation
17th Apr 20237:00 amRNSEdgility rollout progressing ahead of schedule
4th Apr 20233:30 pmRNSAnnual Financial Report
6th Mar 20237:00 amRNSFull Year Results
24th Feb 20237:00 amRNSNotice of Results
1st Feb 20237:00 amRNSAppointment of Chief Financial Officer
9th Jan 20237:00 amRNSBATM receives $26m cyber security order
3rd Jan 20233:30 pmRNSGrant of Options
21st Dec 202212:00 pmRNSResult of AGM
21st Dec 20227:00 amRNSTransaction in Own Shares and TVR
20th Dec 20227:00 amRNSTransaction in Own Shares and TVR
19th Dec 20227:00 amRNSTransaction in Own Shares and TVR
16th Dec 20227:00 amRNSTransaction in Own Shares and TVR
15th Dec 20227:00 amRNSTransaction in Own Shares and TVR
14th Dec 20227:00 amRNSTransaction in Own Shares and TVR
13th Dec 20227:00 amRNSTransaction in Own Shares and TVR
9th Dec 20227:00 amRNSTransaction in Own Shares and TVR
8th Dec 20227:00 amRNSTrading Update
25th Nov 20221:00 pmRNSBlock Listing Interim Review
24th Nov 20224:00 pmRNSNotice of Annual General Meeting
27th Oct 20227:00 amRNSADOR and BIOASTER to develop STI diagnostic tests
18th Oct 20227:00 amRNSMulti-year contract with CityFibre for Edgility
6th Oct 20227:00 amRNSDirectorate Changes
24th Aug 20227:00 amRNSInterim Results
19th Jul 20227:00 amRNSAppointment of CEO of ADOR Diagnostics
11th Jul 20227:00 amRNSBATM partners with CityFibre for Edgility
16th Jun 20224:36 pmRNSPrice Monitoring Extension
26th May 20227:00 amRNSBlock Listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.